Status:
COMPLETED
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
Lead Sponsor:
Medical University of Vienna
Conditions:
Hemophilia A
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and norma...
Eligibility Criteria
Inclusion
- Adult patients with hemophilia A and current antibodies to factor VIII -
Exclusion
- Life-threatening hemorrhage
- Severe liver failure
- Any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury)
- Exposure to other haemostatic drugs during the previous 7 days
- Hypersensitivity to hamster, mouse or bovine proteins
- Known or suspected allergy to NovoSeven or any of its components
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00375323
Last Update
April 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090